Carlsson R M, Claesson B A, Iwarson S A
Department of Infectious Diseases, Ostra Hospital, University of Göteborg, Sweden.
J Hepatol. 1993;18 Suppl 2:S41-5. doi: 10.1016/s0168-8278(05)80377-0.
In this dose-response study evaluating 3 different doses and 2 time schedules, the highest dose, 25 units of viral protein antigen, induced a seroconversion antibody response against hepatitis A virus (anti-HAV) over 10 mIU in all vaccinees by week 3 after one dose, indicating rapid onset of protective antibody levels. Following the second dose, given 4 weeks later, rising titers were observed for 20 weeks, when the third and final dose of 25 units was given. The GMT of anti-HAV at 24 weeks (before the third vaccine injection) was 398 mIU/ml for the 25-unit dose, compared to 42 and 65 mIU/ml, respectively, for the 12.5 unit and 6.25 unit doses. The third vaccine dose at 24 weeks gave a booster response in all vaccinees, but the increase in titers was most pronounced in the 25 unit group, which had reached a GMT of 6593 mIU/ml when tested 4 weeks later. Side-effects included mainly local reactions and a few cases of mild diarrhoea, and did not differ for the 3 doses studied. In Scandinavia, hepatitis A vaccines will probably be used mainly for vaccination of foreign travellers. This category usually requires a rapid immunization schedule with few doses. Two doses approximately 3-4 weeks apart will probably be accepted by most travellers, and a single dose may provide short-term protection for most individuals. The need and timing for a booster dose will have to be further studied.
在这项评估3种不同剂量和2种接种时间表的剂量反应研究中,最高剂量(25单位病毒蛋白抗原)在一剂接种后第3周时,使所有疫苗接种者产生了针对甲型肝炎病毒(抗-HAV)的血清转化抗体反应,抗体水平超过10 mIU,表明保护性抗体水平迅速出现。在4周后接种第二剂后,观察到抗体滴度在20周内持续上升,之后接种第三剂也是最后一剂25单位。24周(在第三次疫苗注射前)时,25单位剂量组抗-HAV的几何平均滴度(GMT)为398 mIU/ml,而12.5单位和6.25单位剂量组分别为42 mIU/ml和65 mIU/ml。24周时的第三剂疫苗在所有疫苗接种者中都引发了加强反应,但滴度增加在25单位组中最为明显,该组在4周后检测时GMT达到了6593 mIU/ml。副作用主要包括局部反应和少数轻度腹泻病例,在所研究的3种剂量之间没有差异。在斯堪的纳维亚半岛,甲型肝炎疫苗可能主要用于外国旅行者的接种。这类人群通常需要快速的免疫接种方案且接种剂量较少。大多数旅行者可能会接受间隔约3 - 4周的两剂接种,而单剂接种可能会为大多数人提供短期保护。加强剂量的必要性和接种时间还需要进一步研究。